Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab + Mitoxantrone in Metastatic HRPC
NCT00385827Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2006
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of siltuximab in prostate cancer (PCa) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events and Serious Adverse Events and Progression Free Survival up to 2 years. Started Nov 2006; status: terminated.
02
Drugs
siltuximab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00385827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385827.